The market is projected to grow from $11B in 2024 to $40B by 2030, driven by both conventional bispecifics and advancements such as antibody-drug and ... Antibody Discovery process can align ...

Bio-Rad is at the forefront of antibody development, leveraging cutting-edge technologies and expertise to address critical challenges in the field. Bio-Rad’s antibody services including HuCAL TM ...

Abcellera, for example, designed Lily’s COVID antibody ... business of drug discovery, find promising targets, and then sell them to pharma to carry out the expensive process of development ...

Phage display remains the most widely used antibody discovery method owing to its versatility, robustness, applicability, and ...

Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline. Artificial ...

With the advent of artificial intelligence (AI), the industry witnessed a rapid transformation in early disease detection, genomic research, drug discovery, clinical processes, and treatment ...

including in the company’s de novo antibody design models – or models that create new antibodies. AI has acquired a vital role in the drug discovery process, transforming the pharmaceutical ...

Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from ...

Manas AI, a full-stack, AI-driven company focused on discovering and advancing next generation medicines, launched today. By leveraging its ...